MiniMed 770G: Automated Insulin Delivery and Monitoring System
Diabetes is one of the world’s leading disease that affecting mankind also associated with obesity and cardiovascular diseases. As per the CDC National Diabetes Statistics Report, 2020 more than 34 million Americans have diabetes and one in five of them don’t even know that they are suffering from it.
Approximately 1.6 million Americans have Type 1 diabetes. 2,10,000 Americans under age 20 are estimated to have diagnosed diabetes, approximately 0.25% of that population. The alarming rates of diabetes throughout the world necessitates the use of Insulin and anti-diabetic drugs.
Administration and Monitoring of Insulin is an arduous task and pose complexity in children in particular. The activities associated with Insulin needs to be closely monitored with advanced and sensitive devices.
In this endeavor the Medtronic’s hybrid closed loop Bluetooth enabled version of MiniMed 770G System was accorded approval by FDA on August 31, 2020. This first legally marketed system was designed to test in children in the age range of 2 to 6 years, it works in such a way that it measures blood glucose levels for every 5 minutes and automatically adjust the Insulin delivery.
The system includes: a sensor that attaches to the body to measure glucose levels under the skin; an insulin pump strapped to the body; and an infusion patch connected to the pump with a catheter that delivers insulin. While the device automatically adjusts insulin levels, users need to manually request insulin doses to counter carbohydrate consumption at mealtime.
MiniMed 770G is a boon to juvenile diabetes patients!
